Chimerix Stock Price, News & Analysis

Chimerix (NASDAQ:CMRX) will host a live conference call on May 4, 2023, at 8:30 a.m. ET to report its financial results for Q1 2023, which ended March 31, 2023. The call will provide a business overview alongside the financial disclosures. Investors can participate by calling (646) 307-1963 domestically or (800) 715-9871 internationally, referring to conference ID 8594205. A live audio webcast will also be available on Chimerix's website, with an archived version accessible two hours post-event.

Chimerix is focused on developing medicines for severe diseases, centered around its advanced clinical program, ONC201, aimed at treating H3 K27M-mutant glioma.

Chimerix (NASDAQ:CMRX) recently presented significant findings at the American Association for Cancer Research (AACR) Annual Meeting, showcasing the efficacy of ONC201 against H3 K27M-mutant glioma. The results indicated that patients treated with ONC201 experienced a statistically significant reversal of the negative epigenetic signature associated with this mutation, a first in clinical trials. These findings, supported by preclinical data, highlight ONC201's ability to penetrate the blood-brain barrier and its potential as a therapeutic agent. Ongoing Phase 3 trials, including the ACTION trial, aim to further validate these promising results.

Chimerix (CMRX) reported a strong financial position with $266 million cash and no debt as of December 31, 2022. The company is focused on advancing its oncology pipeline, particularly ONC201 in the Phase 3 ACTION trial for patients with H3 K27M-mutant glioma, with first data expected in early 2025. Chimerix also noted encouraging preliminary findings for ONC206 in treating glioblastoma patients. For 2022, the company achieved net income of $172.2 million, significantly up from a $173.2 million loss in 2021, primarily due to the TEMBEXA sale. The fourth quarter net loss narrowed to $21 million from $39.5 million the previous year.

Chimerix (NASDAQ:CMRX) announced that its CEO, Mike Sherman, will participate in a Targeted Oncology Panel at the Cowen and Company 43rd Annual Health Care Conference on March 7, 2023, at 2:10 p.m. ET. An audio webcast of the discussion will be available on the company's Investor Relations section of their website, where it will remain archived for approximately 90 days.

Chimerix is focused on developing medicines to improve the lives of patients facing serious diseases, with its most advanced program, ONC201, targeting H3 K27M-mutant glioma.

Chimerix (NASDAQ:CMRX) announced it will host a live conference call on March 2, 2023, at 8:30 a.m. ET to discuss its financial results for the fourth quarter and full year ended December 31, 2022. The conference will provide insights into the company's performance and a business overview.

Participants can join the call by dialing (646) 307-1963 domestically or (800) 715-9871 internationally, using conference ID 9730865. An audio webcast will be accessible in the Investors’ section of Chimerix's website, with an archived version available two hours post-event.

DURHAM, N.C., Jan. 5, 2023 – Chimerix (NASDAQ:CMRX) announced that CEO Mike Sherman will present at the 41^st Annual J.P. Morgan Healthcare Conference on January 12, 2023, at 12:00 p.m. PT in San Francisco, CA.

Investors can access an audio webcast of this presentation on Chimerix's Investor Relations website, where it will be archived for about 90 days. Chimerix focuses on developing medicines that improve the lives of patients with severe diseases, with its leading program, ONC201, targeting H3 K27M-mutant glioma.